PRINCETON, N.J., June 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the appointment of Jerome Zeldis, MD, PhD, Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, and Keith Brownlie, CPA, former partner at Ernst & Young, LLP to its Board of Directors.
"We are delighted to be able to attract the caliber of these two biotechnology industry veterans to the Soligenix Board," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "As Soligenix looks to advance its pipeline, we intend to leverage Jerry Zeldis' experience in helping to grow a very successful company like Celgene into the multibillion dollar, multinational biotechnology company that it is today. Additionally, we are pleased to identify Keith Brownlie, with his wealth of financial expertise in the life science industry, to serve as Chairman of our Audit Committee. Both of these individuals have outstanding records of achievement in their respective fields and we believe they will add significantly to our already diverse and experienced Board of Directors and management team. We look forward to their contributions to our future success, particularly as we get closer to the expected completion of our confirmatory Phase 3 trial of orBec® for the treatment of acute GI GVHD later this year."
Jerome Zeldis, MD, PhD brings extensive drug development experience gained through his career at Celgene, Inc. He is currently Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company, where he has been employed since 1997. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology compa
|SOURCE Soligenix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved